Search
Search Results
- Author(s):
- Weiner, Janet, author
Linas, Benjamin, author
- Publication:
- Philadelphia, PA : Leonard Davis Institute of Health Economics, September 2018
- Subject(s):
- Cost-Benefit Analysis
Hepatitis C -- diagnosis
Mass Screening -- economics
Eligibility Determination
Health Policy
Hepatitis C -- drug therapy
Insurance Coverage -- economics
Mass Screening -- trends
Medicaid -- economics
Sofosbuvir -- economics
Sofosbuvir -- therapeutic use
Practice Guidelines as Topic
Humans
United States
Centers for Disease Control and Prevention (U.S.)
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
- Subject(s):
- Arthritis, Rheumatoid -- drug therapy
Arthritis, Rheumatoid -- immunology
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Drug Therapy, Combination
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Janus Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Tumor Necrosis Factors -- antagonists & inhibitors
Humans
United States
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017
- Subject(s):
- Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic -- drug therapy
Interleukin-4 Receptor alpha Subunit -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors -- therapeutic use
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Cyclosporine -- therapeutic use
Phosphodiesterase 4 Inhibitors -- adverse effects
Phototherapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
- Subject(s):
- Abuse-Deterrent Formulations -- economics
Abuse-Deterrent Formulations -- statistics & numerical data
Analgesics, Opioid -- economics
Analgesics, Opioid -- therapeutic use
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- prevention & control
Prescription Drug Diversion -- statistics & numerical data
Comparative Effectiveness Research
Cost-Benefit Analysis
Delayed-Action Preparations -- economics
Delayed-Action Preparations -- therapeutic use
Drug Compounding -- economics
Drug Overdose -- mortality
Insurance Coverage -- economics
Insurance, Pharmaceutical Services -- economics
Opioid-Related Disorders -- epidemiology
Humans
United States
- Publication:
- Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
- Subject(s):
- Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States
- Publication:
- Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
- Subject(s):
- Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
- Subject(s):
- Immunotherapy, Adoptive
Leukemia, B-Cell -- drug therapy
Lymphoma, B-Cell -- drug therapy
Lymphoma, Non-Hodgkin -- drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Adult
Child
Clinical Trials as Topic
Clofarabine -- therapeutic use
Cost-Benefit Analysis
Immunotherapy, Adoptive -- adverse effects
Immunotherapy, Adoptive -- economics
Receptors, Chimeric Antigen -- therapeutic use
Treatment Outcome
Humans
United States
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
- Subject(s):
- Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
- Subject(s):
- Cystic Fibrosis -- drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator -- therapeutic use
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator -- adverse effects
Treatment Outcome
Humans
United States
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
- Subject(s):
- Endometriosis -- drug therapy
Gonadotropin-Releasing Hormone -- antagonists & inhibitors
Analgesics -- adverse effects
Analgesics -- therapeutic use
Cost-Benefit Analysis
Pain -- drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States
